Literature DB >> 15153937

Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.

Carine Cormary1, Ricardo Gonzalez, Jean-Charles Faye, Gilles Favre, Anne-Françoise Tilkin-Mariamé.   

Abstract

One of the strategies to promote an antitumor response is the genetic modification of tumor cells to induce expression of costimulatory molecules. We have tested the capacity of a soluble form of CD70 molecule (sCD70). After construction of a vector carrying the sCD70, we obtained stable sCD70-secreting TS/A tumor cells and allogenic MC57 fibroblasts. In all, 45% of wild-type (wt) tumors were rejected in immunocompetent mice when transfected sCD70-secreting cells were injected three times in the periphery of the wt tumors. Furthermore, the sCD70-secreting TS/A cells induced a protective memory against wt TS/A tumor growth: 70% of the wt tumors used for the challenge were rejected by mice, which had rejected tumors 45 days before in the presence of sCD70-secreting TS/A cells. It was also shown that in vitro mock TS/A tumor cell proliferation was inhibited by splenocytes harvested from mice injected with TS/A cells expressing CD70. Growth kinetics of wt TS/A tumors in immunocompetent versus nude mice suggested that T lymphocytes were implicated in the antitumor response, which was confirmed by membrane expression of specific markers. The data suggest that injection of genetically transfected cells secreting sCD70 in the periphery of wt TS/A tumors induces T-cell-mediated inhibition of tumor growth and builds up a protective antitumor memory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153937     DOI: 10.1038/sj.cgt.7700708

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

1.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

2.  Collision tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression.

Authors:  Sasis Sirikanjanapong; Biana Lanson; Milan Amin; Frank Martiniuk; Hideko Kamino; Beverly Y Wang
Journal:  Head Neck Pathol       Date:  2010-08-10

3.  Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Authors:  Guillaume Sarrabayrouse; Christine Pich; Raphaël Moriez; Virginie Armand-Labit; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

4.  Effects of Chinese herbal recipes on immunity in immunosuppressive mice.

Authors:  Yongzhan Bao; Cui Jing; Wanyu Shi
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-07-01

5.  CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.

Authors:  P J Adam; J A Terrett; G Steers; L Stockwin; J A Loader; G C Fletcher; L-S Lu; B I Leach; S Mason; A C Stamps; R S Boyd; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2006-08-07       Impact factor: 7.640

6.  CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Authors:  J Trebing; M El-Mesery; V Schäfer; D Weisenberger; D Siegmund; K Silence; H Wajant
Journal:  Cell Death Dis       Date:  2014-01-30       Impact factor: 8.469

7.  CD70: A Potential Target in Breast Cancer?

Authors:  Camille Petrau; Marie Cornic; Philippe Bertrand; Catherine Maingonnat; Vinciane Marchand; Jean-Michel Picquenot; Fabrice Jardin; Florian Clatot
Journal:  J Cancer       Date:  2014-10-22       Impact factor: 4.207

Review 8.  CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.

Authors:  Yu-Huan Yang; Jia-Wei Liu; Chen Lu; Ji-Fu Wei
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

Review 9.  New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).

Authors:  Angelika M Starzer; Anna S Berghoff
Journal:  ESMO Open       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.